Kangliang Lou

Kangliang Lou

Auto-generated profile, based on publicly available information

Kangliang Lou

Fujian Key Laboratory of Precision Diagnosis and Treatment in Breast Cancer and Xiamen Key Laboratory of Endocrine-Related Cancer Precision Medicine, School of Medicine, Xiamen University

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2022 in Biomaterials
Verified
Journal Article
Closed access
PWPeiyuan Wang
Peiyuan Wang
JLJiaqi Li
Jiaqi Li
MWMin Wei
Min Wei
RYRuiqin Yang
Ruiqin Yang
KLKangliang Lou
Kangliang Lou
XLXiaolong Liu
Xiaolong Liu

1 January 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
HZHairong Zhao
Hairong Zhao
SBShuangyan Bao
Shuangyan Bao
SCShuanglong Chen
Shuanglong Chen
QYQingmo Yang
Qingmo Yang
KLKangliang Lou
Kangliang Lou
RYRuiqin Yang
Ruiqin Yang
Purpose: Mastoparan-M (Mast-M) has cytotoxic effects on various tumor cells in vitro, including liver cancer and colorectal cancer. However, the anti-tumor mechanism of Mast-M remains unclear and its potential for anti-tumor therapy has not been investigated. Herein, we aimed to develop a novel phytosome formulation loaded with Mast-M and evaluate its efficacy against breast cancer both in vitro and in vivo. Furthermore, we investigated the underlying anti-tumor mechanisms of Mast-M. Methods: The synthesis of Phy-Mast-M involved a co-solvent technique, followed by solvent evaporation. Its anti-tumor mechanism was investigated using CCK-8, clone formation, and apoptosis assays. Subsequently, the biodistribution and anti-tumor efficacy of Phy-Mast-M were assessed in vivo using the 4T1 tumor-bearing mouse model. Finally, the safety of Phy-Mast-M was evaluated in vivo. Results: The prepared Phy-Mast-M demonstrated an exceptional monodisperse size distribution (125.67 ± 45.79 nm), and exhibited excellent stability under different physiological conditions. Phy-Mast-M could inhibit 4T1 cells growth through multiple channels, including arresting cell growth cycle and disturbing mitochondrial membrane integrity. Phy-Mast-M proved significantly higher accumulation at tumor sites in a tumor-bearing mouse model as compared to free Mast-M. Moreover, in vivo anti-tumor studies demonstrated that Phy-Mast-M exhibited superior curative inhibitory effects on tumor growth and favorable biocompatibility. Conclusion: Phy-Mast-M demonstrates significant anti-tumor activity both in vitro and in vivo. Moreover, its potential for clinical translation suggests promising prospects for cancer therapy, offering more drug options for breast cancer patients.

19 February 2026 in Proceedings of the National Academy of Sciences of the United States of America
Verified
Journal Article
Open access
KLKang-Liang Lou
Kang-Liang Lou
JBJing-Wen Bai
Jing-Wen Bai
HLHong-Tan Liu
Hong-Tan Liu
LLLin-Ling Lin
Lin-Ling Lin
CLCheng-Xi Li
Cheng-Xi Li
GZGuojun Zhang
Guojun Zhang
In early breast cancer surgery (EBC), free margins significantly decrease local recurrence in breast-conserving surgery (BCS), while metastatic status of sentinel lymph node (SLN) impacts axillary management. However, intraoperative visualization of margins and metastatic SLNs (mSLNs) remains challenging. Here, we report a second-window near-infrared (NIR-II) fluorescence probe by conjugating ICG to TROP2-targeting cyclic peptide (TTP-ICG). Our results showed that TTP-ICG specifically binds to TROP2-expressing cells in vitro and identifies TROP2-positive tumors in vivo. In addition, TTP-ICG enabled efficient intraoperative evaluation of surgical margins and visualization of mSLNs at a submillimeter level in preclinical models. Additionally, we optimized the rapid incubation imaging method (RIIM) by shortening the procedure to less than 8 min, illustrating TTP-ICG’s high performance in distinguishing malignant from normal tissues/fibroadenoma lesions as well as detecting metastatic lymph nodes in a cohort of 59 patients. Thus, this TROP2-targeting probe demonstrates its significance for fluorescence imaging-guided surgery with dual applicability in EBC, providing translational potential for further clinical decision-making.